Medication info
Pioglitazone Metformin Tablets 15/850 mg

Pioglitazone Metformin Tablets 15/850 mg

Prescription medicationTablet
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
White to off-white oval film-coated tablets
Packaging
30 tablets (10 tablets/PTP × 3)
Approval status
Active

MFDS item code 201801346 · Approved 2018.03.27 · Insurance code 663607360

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the therapeutic response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in type 2 diabetes treatment may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the therapeutic response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. The components of pioglitazone and metformin work together to effectively lower and control blood sugar levels. In other words, this medication supports the treatment of patients who struggle with blood sugar management, helping to maintain healthy blood sugar levels.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the therapeutic response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in type 2 diabetes treatment may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the therapeutic response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication is used to lower blood sugar and is primarily prescribed for the treatment of type 2 diabetes. During treatment with this medication, renal function is critical; therefore, patients with severely impaired renal function should not use this medication. Moreover, patients with severe heart failure should not take this medication. It is also recommended that patients with compromised liver function avoid using this medication. This medication can cause lactic acidosis, a serious side effect, under conditions such as hypoxia, dehydration, and sepsis, so if such symptoms occur, use should be discontinued immediately. Excessive alcohol consumption is also dangerous, so it is advisable to avoid drinking alcohol while on this medication. This medication should be used cautiously in patients with a history of bladder cancer, and if bladder-related symptoms appear, the physician should be notified immediately. It is advised that pregnant or breastfeeding women do not take this medication. Additionally, safety and efficacy have not been established for children, so this medication is not used in pediatric patients. Elderly patients may have reduced kidney function, so careful dosage adjustment and regular kidney function monitoring are necessary. During the course of this medication, hypoglycemia may occur, so patients should be cautious when skipping meals or engaging in vigorous exercise. In the event of an overdose, immediate medical attention should be sought to receive appropriate treatment, which may include hemodialysis. Finally, this medication may interact with several other drugs, so it is essential to inform the physician or pharmacist of any medications being taken concurrently.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
Show 27 more
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • liver failure
  • congestive heart failure
  • fluid retention
  • fractures
  • blood glucose abnormalities
  • gastroenteritis
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • air in the gastrointestinal tract
  • increased serum creatinine
  • increased blood urea
  • macular edema
  • urinary disorders
  • urgency

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the effectiveness of the medication for an extended period.

Appearance and packaging

Appearance

White to off-white oval film-coated tablets

Package unit

30 tablets (10 tablets/PTP × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.